Thematic Exposure -- 9/10
ISRG is not a diversified medtech company exposed to a theme -- it IS the theme:
robotic-assisted soft-tissue surgery, a monopoly-grade platform riding a high-teens secular growth
curve. Near-monopoly share (~58% of U.S. robotic systems, ~86% of U.S. accessories, 60-80% of the
global soft-tissue robotic market), zero competitors above 15% global, extreme switching costs, and
price-setter status. The oligopoly gate clears decisively. Held to 9 rather than 10 only by decelerating
procedure growth (16% in Q1'26 vs 18% Q4) and credible well-capitalized challengers (Medtronic Hugo,
J&J Ottava) finally entering the soft-tissue field.
Weight: 35%
Robotic Soft-Tissue Surgery -- Monopoly-Grade Platform
Secular Tailwind -- ~16% CAGR TAM
The surgical-robotics market is ~$14-16B in 2026 growing to ~$50-64B by 2035 (~16% CAGR).
Revenue splits into three lines driven by one engine -- the installed base of da Vinci (and Ion)
robots and the procedures run on them. It is a razor/razor-blade model where the high-margin
recurring "blade" (I&A + Services) now dominates the mix at ~77%. da Vinci procedure growth of
+16% YoY (Q1'26) confirms the theme is well above the >10% bar.
Near-Monopoly -- Not Merely a Co-Leader
Oligopoly Gate: PASS
ISRG holds ~58% of U.S. robotic surgical systems, ~86% of U.S. robotic accessories, and 60-80%
of the global soft-tissue robotic market -- comfortably >30% in its primary segment and effectively
a near-monopoly. Zero competitors above 15% global in core soft-tissue robotics. Stryker (Mako) is
the nominal #2 in surgical robotics broadly (~15%), but that is largely orthopedic, not da Vinci's
soft-tissue field. Medtronic Hugo and J&J Ottava remain pre-/early-commercial in the U.S. in 2026.
Ion -- Adjacent Platform, More Contested
Robotic Bronchoscopy / Lung Biopsy
Ion is a smaller but fast-growing diagnostic franchise. ISRG holds an estimated 60-70% share of
robotic biopsy/bronchoscopy, a ~$1.0-1.1B market growing ~16%. Competition here (J&J/Auris Monarch,
Noah Medical Galaxy, Medtronic, Olympus) is more contested than core da Vinci, but ISRG is still
the clear leader. Ion procedures grew +51% in 2025.
Segment Revenue Mix (Q1 2026)
| Segment | Q1'26 Revenue | % of Revenue | Market Share | Theme Growth |
|---|---|---|---|---|
| Instruments & Accessories | $1,686.4M | 60.9% | ~86% of U.S. robotic-surgery accessories | Procedure growth +16% YoY; FY guide 13-15% |
| Systems (da Vinci + Ion) | ~$650.7M | 23.5% | ~58% U.S. / 60-80% global installed soft-tissue robots | Mkt ~$14-16B (2026) to ~$50-64B (2035), ~16% CAGR |
| Services | $433.7M | 15.7% | Captive to ISRG installed base | +19.5% YoY |
| Total | $2,770.8M | 100% | 60-80% global soft-tissue robotic share | +23.0% YoY |
Recurring revenue (I&A + Services) = 76.6% of Q1'26 -- the durable, high-visibility core. Systems is the disclosed residual ($650.7M).
Competitive Gate Questions
| # | Question | Answer |
|---|---|---|
| 1 | Competitors above 15% share? | Core soft-tissue robotics: zero above 15% global. Medtronic Hugo and J&J Ottava remain pre-/early-commercial in the U.S. in 2026. Ion: 2-3 credible competitors, none clearly above 15% vs ISRG's 60-70%. Not fragmented. |
| 2 | Could a customer replace ISRG within 12 months? | No. Hospitals carry multi-hundred-thousand-dollar installed systems, surgeons are credentialed over years, and instruments are proprietary and locked to the system. Switching is a multi-year decision. A genuine moat. |
| 3 | Price-setter or price-taker? | Price-setter. Proprietary single-vendor consumables, recurring usage-limited instruments, and a captive service annuity give ISRG pricing power. |
Oligopoly Gate
| Criterion | Result |
|---|---|
| ISRG global soft-tissue robotic share | 60-80% |
| Any segment >30% share? | Yes (primary segment) |
| Key competitors | Medtronic Hugo, J&J Ottava, Stryker |
| Gate result | PASS |
9/10 — A textbook leader in a growing
theme: a near-monopoly (60-80% global soft-tissue robotic share, ~86% U.S. accessory share) with 77%
recurring revenue, extreme switching costs, and pricing power, attached to a surgical-robotics TAM
compounding ~16% annually. It clears the oligopoly gate decisively and satisfies the price-setter and
non-replaceability tests. Held to 9 rather than 10 only because procedure growth decelerated to 16%
from 18% in Q4, and credible well-capitalized challengers (Medtronic Hugo, J&J Ottava) are finally
entering the soft-tissue field -- a competitive cloud on the horizon even if share is intact today.
This is exactly the dominant-leader-in-a-secular-theme profile the framework prizes.
Data sourced from Daloopa (company_id 439).